ACSL4 and type 2 diabetes mellitus: To address the challenge of managing ACSL4-high HCC patients undergoing TACE, strategies to inhibit ACSL4 activity, such as utilizing rosiglitazone, a clinically available drug for type II diabetes mellitus, are proposed.